Cancer cells may downregulate key components of the type I interferon (IFN-I) signaling pathway, such as cytoplasmic protein kinase dsRNA activated (PKR) [25], retinoic acid-inducible gene I (RIG-I) [26,27], interferon regulatory factors (IRFs) [28], and cell surface IFN-I alpha receptor (IFNAR) [29]. The gene discussed is EIF2AK2; the disease is cancer.